European CHMP recommends approval of azathioprine 10 mg/ml oral suspension (Jayempi) for prophylaxis against transplant rejection and as immunosuppressive antimetabolite

Jayempi is a hybrid medicine of Imurek (azathioprine) 50mg tablets and although has not demonstrated bioequivalence, the differences in the inter and intra-subject variability were not expected to indicate any real difference with the tablet formulation in clinical practice.

Source:

European Medicines Agency